Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dec 21, 2010

Premium

Med BioGene has named Scott Davis to replace David Matthews as chief financial officer. Davis is a partner of Cross Davis & Company, an accounting and management contract services company.


Epigenomics' Chief Financial Officer Oliver Schacht plans to leave the company in March 2011. The company said that it has reached an agreement to hire an "experienced" CFO, whose name the firm will release in January due to confidentiality obligations, to take over the post in April. The company also plans to recruit a new US-based marketing and sales executive to lead its US operations, which are currently run by Schacht.


HistoRx has appointed Jack Davis to serve on its board of directors. Davis is the former President and CEO of Dianon Systems, which was bought by Laboratory Corporation of America in 2002. He also has served as CEO of Calypte Biomedical and worldwide general manager of Abbott Laboratories' Diagnostics Products business.


Rosetta Genomics said this week that Brian Markison has become an observer to the company's board of directors and, upon shareholder approval, will become a director. Markison is chairman and CEO of King Pharmaceuticals and led the company through to its recently announced acquisition by Pfizer. Before that, he was with Bristol-Myers Squibb.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.